Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial.
Chairat Permpikul, Surat Tongyoo, Tanuwong Viarasilpa...
https://pubmed.ncbi.nlm.nih.gov/30704260/Actively Recruiting
Led by Tunis University · Updated on 2024-12-04
200
Participants Needed
1
Research Sites
8 weeks
Total Duration
Sepsis is a serious condition caused by a severe infection leading to widespread inflammation and organ failure. This research evaluates the early use of norepinephrine NE alongside standard treatment to manage low blood pressure and support organ function in patients with severe sepsis. The study aims to determine if starting NE earlier can better restore blood pressure and improve outcomes compared to standard care alone. Participants are randomly assigned to one of two groups. One group receives low-dose norepinephrine infusion early after observing low blood pressure due to sepsis, in addition to usual treatments following the 2021 Surviving Sepsis Campaign guidelines. The other group receives a placebo infusion plus standard therapy. The norepinephrine is given intravenously at a dose adjusted by body weight to maintain target blood pressure. The study monitors treatment over the initial hours and days after sepsis diagnosis. During the study, participants will be closely monitored for blood pressure control within 6 hours, changes in blood lactate levels, the volume of fluids administered within 48 hours, and mortality at 28 days. Researchers will assess organ function and overall response to treatment, following patients throughout their ICU stay and beyond. The trial aims to provide detailed information on the safety and impact of early norepinephrine use in sepsis management.
CONDITIONS
Early Administration of Norepinephrine in Sepsis
A
Ahlem Trifi
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tunis University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 48 hours
Participants receive early administration of norepinephrine or placebo alongside standard sepsis care to manage hypotension caused by sepsis.
Continuous infusion during treatment period with monitoring visits as needed
Duration - 28 days
Participants are monitored for outcomes including shock control, serum lactate levels, fluid volume, and mortality up to 28 days after treatment.
Follow-up visits up to 28 days after treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Chairat Permpikul, Surat Tongyoo, Tanuwong Viarasilpa...
https://pubmed.ncbi.nlm.nih.gov/30704260/Ahlem Trifi, Sami Abdellatif, Asma Mehdi...
https://pubmed.ncbi.nlm.nih.gov/39024364/Tunis University
Lead Sponsor